Q3 2025

Filed Nov 12, 2025 · 10-Q · 43 days after period end · 0001730463-25-000088

Q3 2025 · 10-Q

Revenue

$21.19M

— vs Q3 2024

Net Income

-$79.12M

N/M vs Q3 2024

EPS Diluted

-$0.30

N/M vs Q3 2024

Operating Income-$71,621,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2025	Q3 2024	Q3 2023	Q3 2022
Revenue	$21.19M	$0.00	—	—
Net Income	-$79.12M	-$82.09M	-$45.85M	-$42.77M
EPS Diluted	-$0.30	-$0.31	-$0.26	-$0.47

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR